Belite Bio, Inc (BLTE)

USD 62.96

(-0.16%)

Market Cap (In USD)

1.94 Billion

Revenue (In USD)

-

Net Income (In USD)

-31.63 Million

Avg. Volume

29.68 Thousand

Currency
USD
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
31.005-86.53
PE
-
EPS
-
Beta Value
-1.6
ISIN
US07782B1044
CUSIP
07782B104
CIK
1889109
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Dr. Yu-Hsin Lin M.B.A., Ph.D.
Employee Count
-
Website
https://belitebio.com
Ipo Date
2022-04-29
Details
Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.